Opdivo plus Yervoy combo approved in EU for first-line lung cancer
New approval marks third indication for an Opdivo plus Yervoy-based regimen in the EU
Read Moreby Lucy Parsons | Nov 9, 2020 | News | 0
New approval marks third indication for an Opdivo plus Yervoy-based regimen in the EU
Read Moreby Lucy Parsons | Nov 5, 2020 | News | 0
SGLT2 inhibitor approved for heart failure with reduced ejection fraction
Read Moreby Selina McKee | Jun 3, 2020 | News | 0
Multiple myeloma is the second most common blood cancer, with around 40,000 new cases per year in Europe
Read Moreby Anna Smith | Jan 16, 2020 | News | 0
The J&J division seeks to expand the use to adults with major depressive disorder who have current suicidal ideation with intent.
Read Moreby Selina McKee | Sep 24, 2019 | News | 0
Under the plans, people already living in the EU who have their healthcare funded by the UK will have their healthcare costs covered for six months
Read Moreby Anna Smith | Aug 30, 2019 | News | 0
In July the EMA’s CHMP supported granting a marketing authorisation for the drug.
Read Moreby Anna Smith | Apr 10, 2019 | News | 0
The approval makes it the first PARP inhibitor approved in Europe for the disease.
Read Moreby Selina McKee | Mar 14, 2019 | News | 0
MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).
Read Moreby Selina McKee | Dec 19, 2018 | News | 0
MSD’s Keytruda has been given a green light for use within the EU as an adjuvant treatment for stage III melanoma, and has also been made available on the NHS.
Read Moreby Selina McKee | Nov 16, 2018 | News | 0
The Brexit Health Alliance (BHA) has welcomed the agreement on the terms of the UK’s withdrawal from the European Union (EU).
Read Moreby Selina McKee | Nov 12, 2018 | News | 0
The European Commission expanded the scope of GlaxoSmithKline/Innoviva’s once-daily Trelegy Ellipta to reach more patients with COPD.
Read Moreby Selina McKee | Oct 12, 2018 | News | 0
European regulators have validated Rigel Pharmaceuticals’ application to market fostamatinib for adult chronic immune thrombocytopenia (ITP).
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479